Current Report — Form 8-K — Sect. 13 / 15(d) – SEA’34 Filing Table of Contents
Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 20K
2: EX-10.1 Amendment to the Collaborative Research Agreement HTML 21K
3: EX-99.1 Press Release HTML 11K
Registrant's
telephone number, including area code (734)
335-0468
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common
stock, par value $0.0001 per share
NDRA
The
Nasdaq Stock Market LLC
Warrants,
each to purchase one share of Common Stock
NDRAW
The
Nasdaq Stock Market LLC
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☑
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
On
January 13, 2020, ENDRA Life Sciences Inc. (the
“Company”) entered into Amendment 3 (the
“Amendment”) to that certain Collaborative Research
Agreement between the Company and General Electric Company
(“GE”), dated as of April 22, 2016, as amended by that
certain Amendment 1 to Collaborative Research Agreement, dated
April 21, 2017, and by that certain Amendment 2 to Collaborative
Research Agreement, dated January 30, 2018 (the
“Agreement”). The Amendment extends the term of the
Agreement to January 14, 2021 and modifies certain rights of first
offer held by GE with respect to manufacturing and licensing rights
for the Company’s Thermo-Acoustic Enhanced Ultrasound
technology for use in a fatty liver disease
application.
A copy
of the Amendment is filed as Exhibit 10.1 to this Current Report on
Form 8-K. The foregoing description is not complete and is
qualified in its entirety by reference to the full text of the
Amendment, which is incorporated herein by reference. In the event
of any conflict between this summary and the full text of the
Amendment, the text of the Amendment shall control.
The
information furnished in Item 7.01 of this Current Report on
Form 8-K, including Exhibit 99.1 attached hereto, shall
not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into any
filing under the Securities Act of 1933 or the Exchange Act, except
as expressly set forth by specific reference in such
filing.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.